BRACAnalysis – A test for hereditary breast and ovarian cancer (HBOC) syndrome.
Breast and Ovarian Cancer (HBOC) that runs in the family can occur because of a mutation or alteration in the BRCA1 or BRCA2 genes. If you have a BRCA gene mutation you could have up to an 87% risk of developing breast cancer and up to a 44% risk of developing ovarian cancer in your lifetime.
You may be suitable for the test if you have in either your personal or family history;
- Ovarian cancer
- Breast cancer diagnosed at less than 50 years old
- Two primary breast cancers in the same individual
- Two individuals with breast cancer on the same side of the family
- Male breast cancer
- Triple negative breast cancer
- Pancreatic cancer with an additional HBOC associated cancer
- Ashkenazi Jewish ancestry with an HBOC associated cancer
- A previously identified BRCA mutation in the family
- Comprehensive BRCAnalysis offered to all families with no known mutation
- Single site BRCAnalysis offered to families in which there is a known pathogenic (disease causing) mutation
- Multi-site 3 BRCAnalysis offered to individuals of Jewish heritage who may have cancer themselves or may be unaffected.
In all comprehensive genetic testing there is a chance that the laboratory will identify a change in the genetic sequence, but the clinical importance remains unclear, with our present knowledge. This is an inconclusive result which can cause anxiety to both patients and their doctors.
We send all our genetic samples to Myriad Genetics, based in Salt Lake City, Utah, USA as they have the largest database in the world and so an inconclusive result is now rare.
Myriad update their database in real time as more information becomes available, and if an inconclusive result is identified Myriad will inform the consultant as soon as more information becomes available, and that information will be passed onto the patient who was tested.
We now know that there are several other important breast cancer genes apart from BRCA1 and BRCA2, and we can offer an inherited genetic panel test. This test looks at the sequence of 19 different breast, ovarian and colorectal genes, including the complete sequence of BRCA1 and BRCA2, and gives a more accurate estimate of the risk of developing any of these three common cancers.
We also have a more comprehensive inherited gene panel test, called My Risk, which examines the sequence of 28 different inherited genes involved in 8 common cancers, which can be very useful in patients with a complicated or unusual family history of different cancers.
The process would involve a consultation with Dr James Mackay, Consultant Clinical Genetic Oncologist to discuss your personal risk profile together with the advantages and disadvantages of the various tests available in your specific situation. Myriad have a pipeline of tests in development, and Dr Mackay will discuss with you if there are any new tests available which may be appropriate for you.
If after the consultation you wish to proceed with the genetic test then a blood sample for analysis can be taken at that visit.
It may be that the genetic test is not suitable for you, but it is possible to undertake breast surveillance such as mammography or MRI screening if appropriate.
|Initial Consultation with Dr Mackay||£350|
|Follow up Consultation with Dr Mackay||£125|
|Single site BRCAnalysis||£254|
|Multi-site 3 BRCAnalysis||£309|
|Myriad myRisk 28 Gene Panel||£1,920|
|Intergrated BRCAnalysis with Breast Cancer Panel||£1,500|
|Mammography||£220 - £275|
|Breast Ultrasound||£220 - £265|
Even if you have medical insurance, charges for screening are not routinely covered by medical insurers but some may consider it on a case by case basis because of personal and family history if you contact in advance for pre-authorization. You will be asked to pay all charges on the day, unless you can provide confirmation of full cover, but receipts will be provided for you to submit for reimbursement if this is not available.